본문 바로가기

Case Report: Linezolid-associated toxic optic neuropathy in patients with pulmonary tuberculosis: case series and mini review

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
FRONTIERS IN PHARMACOLOGY16 · #1547236 · 2025
피인용
Web of Science 4Scopus 3
FWCI (Scopus)
1.04
JCR IF
JCR 2024 4.8
ISSN
1663-9812

저자

  1. 윤희진제1저자Pusan Natl Univ, Sch Med, Yangsan Hosp, Dept Ophthalmol, Yangsan, South Korea
  2. 김수진교신저자Pusan Natl Univ, Sch Med, Yangsan Hosp, Dept Ophthalmol, Yangsan, South Korea
  3. 한광언Pusan Natl Univ, Sch Med, Yangsan Hosp, Dept Ophthalmol, Yangsan, South Korea
  4. 최은정Pusan Natl Univ, Res Inst Convergence Biomed Sci & Technol, Yangsan Hosp, Yangsan, South Korea
  5. 이지은Pusan Natl Univ, Sch Med, Yangsan Hosp, Dept Ophthalmol, Yangsan, South Korea

초록

Linezolid is a useful second-line medication for the treatment of tuberculosis that is resistant to multiple drugs. However, long-term therapy can cause side effects, such as optic neuropathy. We describe three cases of progressive painless bilateral visual loss in patients taking long-term linezolid therapy for multidrug-resistant and extensively drug-resistant tuberculosis. We reviewed the literatures and identified 58 cases of linezolid optic neuropathy. Discontinuation of linezolid resulted in a marked improvement in vision, however it was not complete in all patients. Knowledge of visual monitoring of patients undergoing long-term linezolid therapy is important for physicians and ophthalmologists.

키워드

case reportextensive drug resistancelinezolidmuti-drug registancetoxic optic neuropathytuberculosisDRUG-RESISTANT TUBERCULOSISMULTIDRUG-RESISTANTINHIBITIONRECOVERYREGIMENSEFFICACYSAFETY

식별자

Scopus EID
2-s2.0-105006516109
WoS UID
001495122300001